CD274 and hepatocellular carcinoma: In particular, early-phase clinical trials investigating combination regimens that integrate metabolic interference with anti-PD-1/PD-L1 therapies are poised to illuminate the feasibility and potential synergy of dual-targeting approaches in HCC.